Xeltis appoints new Chief Medical Officer

2020-10-01T11:26:11+00:00October 1st, 2020|Latest News|

Jochen Reinöhl joins Xeltis as Chief Medical Officer, bringing to the company extensive experience in medical affairs from his previous role at Edwards Lifesciences. Prior to his corporate career, he worked for over ten years at the Department of [...]

Xeltis joins prestigious research network ArtMoMa

2020-05-12T13:05:47+00:00May 12th, 2020|Latest News|

Xeltis is among seven European companies selected to join the prestigious research network ArtMoMa. The program aims to reach new heights in the emerging field of artificial molecular machines, including supramolecular technology. ArtMoMa is built on synergies and complementarities between [...]

Xeltis’ restorative technology at Biomaterials

2019-06-11T12:52:57+00:00April 3rd, 2019|Latest News|

Preclinical data on Xeltis’ restorative heart valves will illustrate supramolecular materials’ potential application in clinical practice at the Society for Biomaterials annual meeting on Thursday 4 April. Xeltis CTO Martijn Cox will present 2-year preclinical data outlining the capability [...]

Xeltis’ RestoreX™ in Cardiovascular Pathology

2019-06-11T12:55:58+00:00March 8th, 2019|Latest News|

Peer-reviewed journal Cardiovascular Pathology published positive one-year in-vivo data on Xeltis’ RestoreX™ technology platform in its latest issue. According to the paper, preclinical results of RestoreX™ pulmonary graft confirmed the potential of Xeltis’ restorative cardiovascular approach. The study showed that [...]

Xeltis’ new leadership functional to next phase

2019-06-11T12:58:38+00:00March 1st, 2019|Latest News|

Mohammed El-Kurdi, PhD, Vice President for Tissue Science, and Luc Verhees, Senior Vice President for Clinical, Pre-clinical and Medical Affairs, joined Acting CEO Eliane Schutte - Xeltis CDO since 2016 - and CTO and Co-founder Martijn Cox on Xeltis’ leadership [...]

Load More Posts